Payment overview · 2025
General Payments
$329.17
18 reported records · 10 companies
Healthcare provider profile · identity verified
Fred M Heaton, DO
Allopathic & Osteopathic Physicians|Family Medicine · ROARING SPRING, PA · NPI 1720039027
Verified facts
What the public records show
CMS Open Payments records show Fred M Heaton, DO received $329.17 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.08 | 26.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.35 | 15.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.73 | 11.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.63 | 9.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.45 | 9.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.15 | 7.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.63 | 5.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.96 | 5.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.21 | 4.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $13.98 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.17 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.76 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $52.35 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.73 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.73 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 224 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 139 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 30 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
224 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
25 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 641 | 171 |
| Losartan Potassium | Losartan Potassium | 582 | 146 |
| Lisinopril | Lisinopril | 500 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 444 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 401 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 383 | 101 |
| Furosemide | Furosemide | 381 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 311 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 70 |
| Metformin Hcl | Metformin Hcl | 269 | 76 |
| Lorazepam | Lorazepam | 265 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 67 |
| Eliquis | Apixaban | 224 | 49 |
| Simvastatin | Simvastatin | 194 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 59 |
| Gabapentin | Gabapentin | 186 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 168 | 36 |
| Sertraline Hcl | Sertraline Hcl | 157 | 41 |
| Omeprazole | Omeprazole | 142 | 39 |
| Jardiance | Empagliflozin | 139 | 30 |
| Allopurinol | Allopurinol | 137 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 125 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 32 |
| Trazodone Hcl | Trazodone Hcl | 119 | 33 |
| Tramadol Hcl | Tramadol Hcl | 107 | 36 |
| Potassium Chloride | Potassium Chloride | 105 | 26 |
| Ozempic | Semaglutide | 100 | 26 |
| Carvedilol | Carvedilol | 95 | 29 |
| Metformin Hcl Er | Metformin Hcl | 93 | 25 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 91 | 90 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 21 |
| Xarelto | Rivaroxaban | 78 | 15 |
| Finasteride | Finasteride | 74 | 15 |
| Meloxicam | Meloxicam | 74 | 28 |
| Atenolol | Atenolol | 72 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 19 |
| Montelukast Sodium | Montelukast Sodium | 67 | 20 |
| Alendronate Sodium | Alendronate Sodium | 65 | 19 |
| Farxiga | Dapagliflozin Propanediol | 65 | 15 |
| Ezetimibe | Ezetimibe | 61 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 12 |
| Donepezil Hcl | Donepezil Hcl | 58 | 16 |
| Prednisone | Prednisone | 51 | 34 |
| Celecoxib | Celecoxib | 48 | 11 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 12 |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 12 |
| Myrbetriq | Mirabegron | 41 | 11 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 11 |
| Azithromycin | Azithromycin | 39 | 34 |
| Spironolactone | Spironolactone | 39 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Glimepiride | Glimepiride | 36 | 12 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 18 |
| Amoxicillin | Amoxicillin | 30 | 22 |
| Famotidine | Famotidine | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 27 |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 21 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 19 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Glyburide | Glyburide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Multaq | Dronedarone Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.17 · 18 records | Novo Nordisk Inc | ELIQUIS, FARXIGA, Fluad, Flucelvax, JARDIANCE, MOUNJARO, Ozempic, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error